LetsLose Weight Loss and Wellness
LetsLose Weight Loss and Wellness · 4760 Eastern Valley Road · McCalla, AL 35111
4.9· 141 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
About this practice
The McCalla, Alabama, location of LetsLose Weight Loss and Wellness holds 141 Google reviews averaging 4.9 stars, the earliest from 2018 and 6 from the past year. Reviewers mostly mention the staff, followed by results. Per its website, the practice is a six-location group that grew from a single clinic in Central Alabama and says it has served more than 43,000 patients, with physician-supervised programs available in clinic or virtually. Telehealth is listed for this location.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Yes |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-04-29. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.9 across 141 Google reviews. Of the 100 reviews we analyzed, 98 (98%) are positive (4–5★) and 1 (1%) are negative (1–2★).
What patients like
- Friendly, helpful staff54 reviews
- Weight-loss results22 reviews
- Short waits, on-time visits5 reviews
- Knowledgeable, professional providers4 reviews
Common complaints
Very few complaints — only 1 negative review, with no recurring theme.
Most recent Google reviews
Brandi L.★★★★★2026-04-29Staff is nice and welcoming. I’ve lost 75 pounds, and I feel great!
The A.★★★★★2026-04-15Great people
Rickeal G.★★★★★2026-01-06Absolutely love this location everyone so nice and I didn’t realize how I lost weight so easily.
Jason A.★★★★★2026-01-03Cassie and her staff are absolute rockstars!
Jack C.★★★★★2025-12-20Great staff!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs